Jiangsu Recibio Technology CO.
Latest round
- Series C
Last raised
- Jun 2021
Total raised
- $383M
Investors
- 25
About Jiangsu Recibio Technology CO.
, Ltd. previous known as RecBio, operates as a biotechnology company that specializes in the development of genetic engineering vaccines. In January 2019, the company merged with Anbaisheng Biotechnology. In March 2022, the company was listed on the Hongkong Stock Exchange under the number 02179. The company has a vaccines candidates portfolio consisting of 12 vaccine candidates, including recombinant HPV vaccine, recombinant COVID-19 vaccine, recombinant shingles vaccine, Virus vector adult TB vaccine, recombinant influenza quadrivalent vaccine. The company's core product is the recombinant HPV 9-valent vaccine to prevent cervical cancer which is currently under phase III clinical trial. For the recombinant HPV 9-valent vaccine, REC603, the company has completed subject enrollment and plans to complete the three-shot dosing in the first half of 2022, and to submit the BLA application to the NMPA by 2025. Also, the company developed two recombinant HPV bivalent vaccine candidates, REC601 and REC602, which both are under phase I clinical trial in China. The company plans to continue to optimize, develop and commercialize the HPV vaccine pipeline, perform preclinical and clinical studies, registration of COVID-19 vaccine, and other vaccines.
Who invested in Jiangsu Recibio Technology CO.
25 investors across 4 rounds
See all investors in Jiangsu Recibio Technology CO.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Jiangsu Recibio Technology CO.
Who invested in Jiangsu Recibio Technology CO.?
Jiangsu Recibio Technology CO. has 25 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Jiangsu Recibio Technology CO. raised?
Jiangsu Recibio Technology CO. has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Jiangsu Recibio Technology CO. last raise money?
Jiangsu Recibio Technology CO.'s most recent round on record is a Series C, in Jun 2021.
What does Jiangsu Recibio Technology CO. do?
Jiangsu Recibio Technology CO. is a biotechnology company.
Where is Jiangsu Recibio Technology CO. headquartered?
Jiangsu Recibio Technology CO. is headquartered in Taizhou, China.
Which VCs invest in companies like Jiangsu Recibio Technology CO.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Jiangsu Recibio Technology CO.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Jiangsu Recibio Technology CO.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.